- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04492904
Singapore COVID-19 Chemosensory Tracking (SCCT) Study
The study aims to longitudinally track the onset, severity and recovery of changes in chemosensory acuity (smell and/or taste loss) among those suspected of COVID-19 infection. Using standardised questionnaire and testing approaches, the investigators aim to objectively characterise and measure temporal changes in taste and smell to confirm the prevalence of these symptoms as an early marker of infection. Information on symptoms experience, changes in appetite and food-related quality of life will be also be assessed via questionnaire.
The results of the study will help individuals who experience a loss of smell and/or taste to self-isolate and/or self-refer to a medical professional, if an association between smell and/or taste and COVID-19 infection is found.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will be a retrospective-prospective, longitudinal case-control observational study using a convenience sample drawn from patients presenting for COVID-19 screening, and will recruit both males and females above the age of 21 years who consent to provide anonymised data online on recent changes to their taste and smell. There will be no intervention (medication or foods) as part of this study. Potential participants will be screened to ensure they meet the study inclusion and exclusion criteria and all participants will sign an informed consent.
During their first recruitment session at the hospital/clinic, participants will be required to complete a series of questionnaires to record recent changes in taste and smell sensitivity. The series of questionnaires will include: Singapore Smell and Taste Questionnaire (SSTQ), Sino-nasal Outcome Test-22 (SNOT-22) and optionally, the Global Consortium of Chemosensory Research Questionnaire (GCCRQ). The purpose of administering the different questionnaires is to cover wide range of complementary questions that capture information related to changes in taste and smell function associated with COVID-19 infection. Thereafter participants will be briefed on how to complete the home-use standardized smell and taste test (Home-use Test). The Home-use Test (HUT) will be completed daily over a 28 day period at participants place of residence, to enable self-monitoring of changes to smell and taste abilities. During the HUT, participants will rate their sense of smell using the two standardised odour pens they are provided on the first day of their session at the hospital/ clinic. For each pen, participants will be asked to identify the odour and rate the perceived intensity. This will then be followed a taste test where participants will take a small quantity of a powder representing each of the four prototypical basic tastes sweet (sugar), salt (table salt), bitter (coffee powder or tea) and sour (lime powder), to the tip end of their tongue with a small spoon to taste. Participant are asked to self-report that they confirm that can identify the taste quality and to rate the perceived intensity on line scales provided in an online questionnaire. All measures are self-administered and completed independently by the participant, with responses captured using unique identifier code for each participant through an online software (CompuSense, Guelph, Ontario). During the 28-day home use test period, once a week participants will be asked to complete a 'Follow-up Questionnaire' which will assess how the symptoms experienced have impacted their enjoyment of food, appetite and food-related quality of life.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Singapore, Singapore, 117599
- Clinical Nutrition Research Centre, Singapore
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age 21 years and above
- Residing in Singapore for the next 28 days.
- Possess a mobile device with 4G network and knows how to use mobile apps (i.e. QR scanner)
Exclusion Criteria:
- Unable to provide informed consent
- Allergic/ intolerant to test items (i.e. fragrances, sugar, salt, coffee or lime powder)
- Not agreeable with the study team accessing your medical records
- For women: Pregnant
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Other
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
COVID-19 Positive (Case)
Participants who were present for COVID-19 screening and their test results will later indicate positive of infection.
Participants will complete a one-time assessment of the various online questionnaires (Singapore Smell and Test Questionnaire, Sino-nasal Outcome Test-22, and Global Consortium for Chemosensory Research Questionnaire - Optional) in the hospital/clinic.
Taste and smell acuity, as well as experienced symptoms, changes in appetite and food-related quality of life will be assessed using the Home-use Tests and Follow-up questionnaire over a period of 28 days.
|
Prospective tracking of changes in taste and smell acuity, and related changes in appetite, enjoyment of food and food-related quality of life will be assessed using the Home-use Tests and Follow-up questionnaire over a period of 28 days.
|
COVID-19 Negative/Other respiratory diseases (Control)
Participants who were present for COVID-19 screening and their test results will later indicate negative of infection.
Participants will complete a one-time assessment of the various online questionnaires (Singapore Smell and Test Questionnaire, Sino-nasal Outcome Test-22, and Global Consortium for Chemosensory Research Questionnaire - Optional) in the hospital/clinic.
Taste and smell acuity, as well as experienced symptoms, changes in appetite and food-related quality of life will be assessed using the Home-use Tests and Follow-up questionnaire over a period of 28 days
|
Prospective tracking of changes in taste and smell acuity, and related changes in appetite, enjoyment of food and food-related quality of life will be assessed using the Home-use Tests and Follow-up questionnaire over a period of 28 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Taste and smell acuity
Time Frame: 28 days
|
Taste and smell functions of all participants will be assessed as part of the Home-use Test using taste test items (i.e.
sweet: sugar, salty: salt, sour: lime powder and bitter: coffee powder) and odour pens respectively.
Participants will identify the taste/smell and rate the perceived intensity on a Visual Analogue Scale (VAS) from 'not strong at all' (0) to 'extremely strong taste/smell' (100).
A higher score will indicate greater intensity of taste/smell perceived.
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Experienced symptoms, changes in appetite and food-related quality of life
Time Frame: 28 days
|
Experienced symptoms, changes in appetite and food-related quality of life will be assessed as part of the Follow-up questionnaire.
|
28 days
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Ciaran Forde, Phd, Clinical Nutrition Research Centre, Singapore
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020/00810
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on Home-use Test and Follow-up Questionnaire
-
University Hospital, Basel, SwitzerlandCompleted
-
Ghana Health ServicesUniversity of Warwick; Ellembelle District Health Directorate GhanaCompletedPregnant Women | Home VisitsGhana
-
Deutsches Herzzentrum MuenchenCompletedImprovement of Treatment SatisfactionGermany
-
University of IcelandMemorial Sloan Kettering Cancer Center; Landspitali University Hospital; deCODE... and other collaboratorsActive, not recruitingMonoclonal Gammopathy of Undetermined SignificanceIceland
-
Direction Centrale du Service de Santé des ArméesRecruitingCOVID-19 | Sars-CoV-2 InfectionFrance
-
University Hospital, CaenCompleted
-
Tourcoing HospitalRecruiting
-
Oslo University HospitalRecruitingKidney Transplant Failure and RejectionNorway
-
Nantes University HospitalUniversity Hospital, Strasbourg, France; University Hospital, Clermont-Ferrand and other collaboratorsActive, not recruitingSingle or Dual Chamber Pacemaker Implantation | Home Monitoring Follow-upFrance
-
University Hospital, AngersUnknownPost Partum | DeliveryFrance